Overview
Compare with Lexeo Therapeutics, Inc., ImageneBio, Inc. or Compass Therapeutics, Inc., or pick any stock.
- TickerCRDF on Nasdaq2
- IndustryBiological Products, (No Diagnostic Substances)2
- HeadquartersSan Diego, United States2
- Incorporated inDE3
- Business address11055 Flintkote Avenue, San Diego, Ca 921213
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI549300AHOLZBHHYFWP042
- StatusActive2
- LEI statusIssued and current2
- Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 47331342
See how the biggest companies compare on our leaderboards
Our operations and business prospects are always subject to risks and uncertainties including, among others:4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-8256.3%Operating margin5
-7732.0%Net margin5
-13.2%Revenue growth, 20255
-101.0%Return on equity5
-$38.0MFree cash flow5
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Selling, general and admin100¢$14.2M
Out of $593.0K in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Royalty revenues | $593.0K | $683.0K |
| Research and development | $35.3M | $36.9M |
| Selling, general and administrative | $14.2M | $12.5M |
| Total operating expenses | $49.6M | $49.3M |
| Loss from operations | -$49.0M | -$48.7M |
| Interest income | $3.1M | $3.3M |
| Other income (expense), net | $5.0K | -$39.0K |
| Total other income (expense), net | $3.1M | $3.2M |
| Net loss | -$45.9M | -$45.4M |
| Preferred stock dividend payable on Series A Convertible Preferred Stock | -$25.0K | -$24.0K |
| Net loss attributable to common stockholders | -$45.9M | -$45.5M |
| Net loss per common share - basic | -$0.69 | -$0.95 |
| Net loss per common share - diluted | -$0.69 | -$0.95 |
| Weighted-average shares outstanding - basic | 66.8M shares | 47.6M shares |
| Weighted-average shares outstanding - diluted | 66.8M shares | 47.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $17.5M | $51.5M | |
| Short-term investments | $40.8M | $40.3M | |
| Accounts receivable and unbilled receivable | $182.0K | $773.0K | |
| Prepaid expenses and other current assets | $1.6M | $2.5M | |
| Total current assets | $60.1M | $95.1M | |
| Property and equipment, net | $578.0K | $898.0K | |
| Operating lease right-of-use assets | $629.0K | $1.2M | |
| Other assets | $549.0K | $69.0K | |
| Total Assets | $61.9M | $97.2M | |
| Accounts payable | $8.1M | $4.8M | |
| Accrued liabilities | $7.6M | $7.9M | |
| Operating lease liabilities | $730.0K | $710.0K | |
| Total current liabilities | $16.4M | $13.4M | |
| Operating lease liabilities, net of current portion | $102.0K | $813.0K | |
| Total Liabilities | $16.5M | $14.2M | |
| Preferred stock, $0.001 par value, 20,000 shares authorized; 277 designated as Series A Convertible Preferred Stock; 61 shares outstanding at December 31, 2025 and December 31, 2024 with liquidation preference of $1,117 and $1,092 at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Common stock, $0.0001 par value, 150,000 shares authorized; 68,305 and 66,524 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $7.0K | $7.0K | |
| Additional paid-in capital | $475.4M | $467.1M | |
| Accumulated other comprehensive gain | $50.0K | $34.0K | |
| Accumulated deficit | -$430.0M | -$384.2M | |
| Total stockholders equity | $45.4M | $82.9M | $69.7M |
| Total liabilities and stockholders equity | $61.9M | $97.2M | |
| Preferred Stock, par value (in USD per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 20.0M shares | 20.0M shares | |
| Temporary equity, shares authorized (in shares) | 277.0K shares | 277.0K shares | |
| Temporary equity, shares outstanding (in shares) | 61.0K shares | 61.0K shares | |
| Preferred stock, liquidation preference, value | $1.1M | $1.1M | |
| Common stock, par value (in USD per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 150.0M shares | 150.0M shares | |
| Common stock, shares issued (in shares) | 68.3M shares | 66.5M shares | |
| Common stock, shares outstanding (in shares) | 68.3M shares | 66.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $17.5M | $51.5M | |
| Short-term investments | $40.8M | $40.3M | |
| Accounts receivable and unbilled receivable | $182.0K | $773.0K | |
| Prepaid expenses and other current assets | $1.6M | $2.5M | |
| Total current assets | $60.1M | $95.1M | |
| Property and equipment, net | $578.0K | $898.0K | |
| Operating lease right-of-use assets | $629.0K | $1.2M | |
| Other assets | $549.0K | $69.0K | |
| Total Assets | $61.9M | $97.2M | |
| Accounts payable | $8.1M | $4.8M | |
| Accrued liabilities | $7.6M | $7.9M | |
| Operating lease liabilities | $730.0K | $710.0K | |
| Total current liabilities | $16.4M | $13.4M | |
| Operating lease liabilities, net of current portion | $102.0K | $813.0K | |
| Total Liabilities | $16.5M | $14.2M | |
| Preferred stock, $0.001 par value, 20,000 shares authorized; 277 designated as Series A Convertible Preferred Stock; 61 shares outstanding at December 31, 2025 and December 31, 2024 with liquidation preference of $1,117 and $1,092 at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Common stock, $0.0001 par value, 150,000 shares authorized; 68,305 and 66,524 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $7.0K | $7.0K | |
| Additional paid-in capital | $475.4M | $467.1M | |
| Accumulated other comprehensive gain | $50.0K | $34.0K | |
| Accumulated deficit | -$430.0M | -$384.2M | |
| Total stockholders equity | $45.4M | $82.9M | $69.7M |
| Total liabilities and stockholders equity | $61.9M | $97.2M | |
| Preferred Stock, par value (in USD per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 20.0M shares | 20.0M shares | |
| Temporary equity, shares authorized (in shares) | 277.0K shares | 277.0K shares | |
| Temporary equity, shares outstanding (in shares) | 61.0K shares | 61.0K shares | |
| Preferred stock, liquidation preference, value | $1.1M | $1.1M | |
| Common stock, par value (in USD per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 150.0M shares | 150.0M shares | |
| Common stock, shares issued (in shares) | 68.3M shares | 66.5M shares | |
| Common stock, shares outstanding (in shares) | 68.3M shares | 66.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$45.9M | -$45.4M |
| Depreciation | $364.0K | $404.0K |
| Stock-based compensation expense | $5.7M | $4.8M |
| Amortization of right-of-use assets | $540.0K | $539.0K |
| Accretion of discounts on short-term investments, net | -$848.0K | -$598.0K |
| Accounts receivable and unbilled receivable | $591.0K | -$484.0K |
| Prepaid expenses and other current assets | $557.0K | -$452.0K |
| Other assets | -$480.0K | $1.2M |
| Accounts payable and accrued liabilities | $2.2M | $3.0M |
| Operating lease liabilities | -$691.0K | -$626.0K |
| Net cash used in operating activities | -$37.9M | -$37.7M |
| Capital expenditures | -$44.0K | -$80.0K |
| Maturities of short-term investments | $71.1M | $27.1M |
| Purchases of short-term investments | -$71.9M | -$23.6M |
| Sales of short-term investments | $2.1M | $10.3M |
| Net cash provided by investing activities | $1.3M | $13.7M |
| Proceeds from sales of common stock, net of expenses of $0 and $3,286, respectively | $0 | $53.4M |
| Proceeds from exercise of warrants, net of expense of $169 and $0, respectively | $2.1M | $0 |
| Proceeds from exercise of options | $493.0K | $373.0K |
| Net cash provided by financing activities | $2.6M | $53.8M |
| Net change in cash and cash equivalents | -$34.0M | $29.8M |
| Cash paid for taxes | $1.0K | $1.0K |
| Purchases of unsettled short-term investments included in accrued liabilities | $744.0K | $0 |
| Stock issuance expenses | $0 | $3.3M |
| Exercise of warrants | $169.0K | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
Cardiff Oncology, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Cardiff Oncology, Inc.
- BlackRock Filed SCHEDULE 13G/A on Cardiff Oncology, Inc., latest Jul 27, 2026 (7 filings since Feb 4, 2022)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Cardiff Oncology, Inc., latest Mar 26, 2026 (2 filings since Jul 29, 2025)
- Commodore Capital LP Filed SCHEDULE 13G/A on Cardiff Oncology, Inc., latest Aug 14, 2025 (2 filings since Dec 17, 2024)
- Pfizer Filed SCHEDULE 13G/A on Cardiff Oncology, Inc., latest Feb 12, 2025 (2 filings since Nov 19, 2021)
- ACORN BIOVENTURES, L.P. Filed SC 13G/A on Cardiff Oncology, Inc., latest Feb 6, 2024 (3 filings since Jan 26, 2023)
- CAXTON CORP Filed SC 13G/A on Cardiff Oncology, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- Janus Henderson Group Ltd. Filed SC 13G/A on Cardiff Oncology, Inc., latest Feb 9, 2023 (2 filings since Feb 10, 2022)
- Avidity Partners Management LP Filed SC 13G/A on Cardiff Oncology, Inc., latest Feb 14, 2022
- Corriente Advisors, LLC Filed SC 13G/A on Cardiff Oncology, Inc., latest Feb 14, 2022
- State Street Corporation Filed SC 13G/A on Cardiff Oncology, Inc., latest Feb 9, 2022
- Cardiff Oncology, Inc. San Diego, California, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Cardiff Oncology, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $5.0M5 Dec 31, 2025 | $5.0M5 Dec 31, 2024 | +0.2% |
| Accumulated depreciation | $4.5M5 Dec 31, 2025 | $4.1M5 Dec 31, 2024 | +8.0% |
| Property and equipment, net | $578.0K5 Dec 31, 2025 | $898.0K5 Dec 31, 2024 | −35.6% |
| Operating-lease assets (leased space) | $629.0K5 Dec 31, 2025 | $1.2M5 Dec 31, 2024 | −46.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $17.5M5 Dec 31, 2025 | $51.5M5 Dec 31, 2024 | −66.1% |
| Marketable securities, current | $40.8M5 Dec 31, 2025 | $40.3M5 Dec 31, 2024 | +1.4% |
| Marketable securities, non-current | $8.9M5 Dec 31, 2025 | $6.3M5 Dec 31, 2024 | +41.7% |
| Debt securities available for sale | $40.8M5 Dec 31, 2025 | $40.3M5 Dec 31, 2024 | +1.4% |
Properties, in its own words
We currently lease laboratory and office space for our headquarters in San Diego, California under a lease agreement, as amended from time to time, that expires in February 2027. We believe that our facilities are adequate for our current and near-term needs.
Item 2 of the 10-K filed Feb 24, 2026.4
Leadership
Who has led Cardiff Oncology, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerMani Mohindru Feb 18, 2026 to now13
- Chief executive officerMark Erlander May 18, 2020 to Feb 18, 202614
- Chief executive officerWilliam J. Welch Apr 27, 2016 to Feb 1, 201815
- Chief executive officerAntonius Schuh Jan 24, 2012 to Jan 6, 201616
- Chief financial officerJoshua B. Muntner Apr 16, 2026 to now17
- Chief financial officerJames E. Levine Jul 12, 2021 to Apr 16, 202618
- Chief financial officerSteve Zaniboni Jan 24, 2012 to Apr 22, 201619
- Chief operating officerAjay Aggarwal Apr 28, 2026 to now20
- Chief operating officerVicki Kelemen Jun 22, 2020 to Mar 16, 202321
Board members and other officers (26)
- Chief Accounting OfficerBrigitte Ute Lindsay Feb 9, 2026 to now22
- Chief Medical OfficerRoger Sidhu Jul 8, 2025 to now23
- Chief Medical OfficerFairooz Kabbinavar Feb 9, 2023 to now24
- Chief Scientific OfficerTod Smeal Jan 14, 2022 to now25
- Chief Medical OfficerKatherine L. Ruffner Jul 13, 2021 to Mar 10, 202226
- Chief Scientific OfficerMark Erlander Aug 24, 2015 to Jan 3, 202027
- Chief Commercial OfficerMatthew L. Posard Aug 24, 2015 to Jan 6, 201628
- Board memberMani Mohindru Jun 14, 2021 to now29
- Board memberRenee P. Tannenbaum Jun 14, 2021 to now30
- Board memberGary W. Pace Apr 22, 2020 to now31
- Board memberJames O. Armitage Apr 22, 2020 to now32
- Board memberLale White Apr 30, 2020 to now33
- Board memberMark Erlander Jun 19, 2020 to now34
- Board memberAthena Countouriotis Sep 20, 2017 to Jun 24, 201935
- Board memberWilliam J. Welch Dec 19, 2016 to Feb 1, 201836
- Board memberCarl B. Feldbaum Jan 6, 2015 to Mar 19, 201537
- Board memberSteve Zaniboni Jan 2, 2014 to Jan 2, 201438
- Board memberRodney S. Markin Feb 21, 2014 to now39
- Board memberChristopher McGuigan Jan 16, 2013 to Feb 21, 201340
- Board memberJohn P. Brancaccio Jan 23, 2012 to Mar 10, 202241
- Board memberStanley Tennant Jan 23, 2012 to Jun 13, 201842
- Board memberAntonius Schuh Jan 24, 2012 to Jan 6, 201616
- Board memberGabriel Cerrone Jan 24, 2012 to Feb 21, 201343
- Board memberGary S. Jacob Jan 24, 2012 to Mar 23, 202144
- Board memberAbba David Poliakoff Jan 9, 2008 to Jan 9, 200845
- Board memberKira Sheinerman Jun 19, 2008 to Aug 14, 200846
Former names
Timeline
- Sep 14, 20268-K Entered a material agreement; Regulation FD disclosure47
- Aug 11, 20268-K Results of operations48
- Jul 16, 20268-K Entered a material agreement; Other events49
- Jun 11, 20268-K Shareholder vote50
- Jun 3, 20268-K Regulation FD disclosure51
- May 29, 20268-K Entered a material agreement52
- May 19, 20268-K Other events53
- May 14, 20268-K Results of operations54
- Apr 9, 20268-K Executive or director change; Other events55
- Apr 2, 20268-K Entered a material agreement; Executive or director change56
- Feb 25, 20268-K Regulation FD disclosure57
- Feb 24, 20268-K Completed an acquisition or sale58
- Feb 18, 2026New chief executive Mani Mohindru becomes CEO13
- May 18, 2020New chief executive Mark Erlander becomes CEO14
- Apr 27, 2016New chief executive William J. Welch becomes CEO15
- Jan 24, 2012New chief executive Antonius Schuh becomes CEO16
- Sep 21, 2009Founded Cardiff Oncology, Inc. is founded2
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.17) a share, on Nov 6, 2025.59
When it reported results
- Aug 11, 2026Reported quarterly or annual results48
- May 14, 2026Reported quarterly or annual results54
- Nov 6, 2025Reported quarterly or annual results60
- Jul 29, 2025Reported quarterly or annual results61
- May 8, 2025Reported quarterly or annual results62
- Feb 27, 2025Reported quarterly or annual results63
- Nov 7, 2024Reported quarterly or annual results64
- Aug 8, 2024Reported quarterly or annual results65
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
216 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 60 major events, 77 insider forms, 23 large holders, 36 other. The latest 20:
- Sep 14, 20268-K EDGAR
- Aug 26, 2026DEFA14A EDGAR
- Aug 26, 2026DEF 14A EDGAR
- Aug 14, 2026PRE 14A EDGAR
- Aug 11, 20268-K EDGAR
- Aug 11, 202610-Q EDGAR
- Jul 27, 2026SCHEDULE 13G/A EDGAR
- Jul 21, 2026S-8 EDGAR
- Jul 16, 20264 EDGAR
- Jul 16, 20264 EDGAR
- Jul 16, 20268-K EDGAR
- Jul 16, 2026424B5 EDGAR
- Jun 22, 20264 EDGAR
- Jun 22, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 11, 20268-K EDGAR
The 216 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
18 open-market trades by officers, directors and large owners since October 2021: 18 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 14, 2026 | PACE GARY WDirector | Buy | 687,285 | $1.46 | $1.0M | Form 4 |
| Jul 14, 2026 | Mohindru ManiChief Executive Officer | Buy | 34,364 | $1.46 | $50.2K | Form 4 |
| Jun 18, 2026 | Mohindru ManiChief Executive Officer | Buy | 24,703 | $1.21 | $29.9K | Form 4 |
| Jun 18, 2026 | PACE GARY WDirector | Buy | 30,000 | $1.22 | $36.6K | Form 4 |
| Jul 30, 2025 | PACE GARY WDirector | Buy | 290,000 | $2.45 | $710.5K | Form 4 |
| Dec 18, 2024 | Levine James E.Chief Financial Officer | Buy | 2,400 | $5.00 | $12.0K | Form 4 |
| Dec 17, 2024 | Levine James E.Chief Financial Officer | Buy | 2,752 | $5.42 | $14.9K | Form 4 |
| Dec 16, 2024 | Levine James E.Chief Financial Officer | Buy | 2,564 | $3.83 | $9.8K | Form 4 |
| Dec 12, 2024 | TANNENBAUM RENEE PDirector | Buy | 10,000 | $3.42 | $34.2K | Form 4 |
| Dec 11, 2024 | PACE GARY WDirector | Buy | 361,615 | $2.60 | $940.2K | Form 4 |
| Dec 19, 2023 | PACE GARY WDirector | Buy | 30,000 | $1.37 | $41.1K | Form 4 |
| Nov 10, 2023 | PACE GARY WDirector | Buy | 22,950 | $0.98 | $22.5K | Form 4 |
| Nov 25, 2022 | Erlander MarkChief Executive Officer | Buy | 10,000 | $1.43 | $14.3K | Form 4 |
| Sep 19, 2022 | White LaleDirector | Buy | 15,000 | $1.64 | $24.6K | Form 4 |
| Sep 16, 2022 | Armitage James ODirector | Buy | 13,000 | $1.56 | $20.3K | Form 4 |
| Sep 16, 2022 | Levine James E.Chief Financial Officer | Buy | 30,000 | $1.56 | $46.8K | Form 4 |
| Sep 15, 2022 | TANNENBAUM RENEE PDirector | Buy | 10,000 | $1.72 | $17.2K | Form 4 |
| Sep 15, 2022 | PACE GARY WDirector | Buy | 150,000 | $1.71 | $256.5K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BlackRockSCHEDULE 13G/A, 7 filings Feb 4, 2022 to Jul 27, 202666
- VANGUARD GROUP INCSCHEDULE 13G/A, 2 filings Jul 29, 2025 to Mar 26, 202667
- Commodore Capital LPSCHEDULE 13G/A, 2 filings Dec 17, 2024 to Aug 14, 202568
- PfizerSCHEDULE 13G/A, 2 filings Nov 19, 2021 to Feb 12, 202569
- ACORN BIOVENTURES, L.P.SC 13G/A, 3 filings Jan 26, 2023 to Feb 6, 202470
- CAXTON CORPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202371
- Janus Henderson Group Ltd.SC 13G/A, 2 filings Feb 10, 2022 to Feb 9, 202372
- Avidity Partners Management LPSC 13G/A, 1 filing Feb 14, 202273
- Corriente Advisors, LLCSC 13G/A, 1 filing Feb 14, 202274
- State Street CorporationSC 13G/A, 1 filing Feb 9, 202275
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Laurion Capital Management LP | 3,098,299 | $4.0M | 0.3% | +451,561 |
| Vanguard Capital Management LLC | 2,895,592 | $3.8M | 0.0% | +39,626 |
| Pfizer Inc | 2,411,575 | $3.0M | 1.8% | No change |
| Franklin Resources Inc | 1,205,803 | $1.6M | 0.0% | No change |
| BlackRock, Inc. | 972,873 | $1.3M | 0.0% | −3,008,514 |
| Blair William & Co/il | 912,513 | $1.2M | 0.0% | −9,894 |
| Geode Capital Management, LLC | 820,062 | $1.1M | 0.0% | −779,601 |
| UBS Group AG | 638,699 | $830.3K | 0.0% | +238,123 |
| Jane Street Group, LLC | 607,900 | $790.3K | 0.0% | +567,795 |
| Vanguard Fiduciary Trust Co | 410,602 | $533.8K | 0.0% | −35,623 |
| Aqr Capital Management LLC | 346,353 | $450.3K | 0.0% | +280,197 |
| State Street Corp | 331,395 | $430.8K | 0.0% | −855,552 |
| Flputnam Investment Management Co | 247,474 | $321.7K | 0.0% | −347,653 |
| Morgan Stanley | 246,095 | $319.9K | 0.0% | +189,789 |
| Bnp Paribas Financial Markets | 228,461 | $297.0K | 0.0% | +215,385 |
| Marshall Wace, Llp | 162,214 | $210.9K | 0.0% | New |
| Bank of New York Mellon Corp | 161,689 | $210.2K | 0.0% | −141,739 |
| Northern Trust Corp | 152,875 | $198.7K | 0.0% | −340,330 |
| Avestar Capital, LLC | 136,145 | $177.0K | 0.0% | No change |
| Millennium Management LLC | 134,517 | $174.9K | 0.0% | +111,488 |
| Assenagon Asset Management S.A. | 134,462 | $174.8K | 0.0% | +67,231 |
| Qube Research & Technologies Ltd | 125,550 | $163.2K | 0.0% | New |
| Goldman Sachs Group Inc | 120,827 | $157.1K | 0.0% | −14,771 |
| Susquehanna International Group, Llp | 116,138 | $151.0K | 0.0% | +23,779 |
| AlphaCore Capital LLC | 108,493 | $141.0K | 0.0% | +67 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Cardiff Oncology, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARCardiff Oncology, Inc.1
- CIK0001213037
- Employer ID (EIN)27-20043824
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address11055 Flintkote Avenue, San Diego, CA 921211
- Phone858-952-75701
- Shares outstanding77,795,249 as of Aug 6, 202612
- Public float$205.4M as of Jun 30, 20254
- AuditorBDO USA, P.C., San Diego, California PCAOB ID 243; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceJan 7, 20031
- Filings1,193 in all: 8-K (458), 4 (251), 10-Q (46), 3 (34), CORRESP (34), SC 13G (30), SC 13G/A (28), UPLOAD (26)1
All 54 form types
DEFA14A (21), DEF 14A (20), 424B5 (19), EFFECT (17), 10-K (15), 4/A (14), S-8 (13), 10QSB/A (12), S-1/A (12), D (11), 10QSB (10), 8-K/A (10), SB-2/A (10), NT 10-Q (8), S-3 (8), 424B3 (7), POS AM (7), PRE 14A (7), S-1 (7), REGDEX (6), SCHEDULE 13G/A (5), ARS (4), CT ORDER (4), 10-12G/A (3), 10KSB (3), 10KSB/A (3), 424B4 (3), NT 10-K (3), SCHEDULE 13G (3), 10-Q/A (2), S-3/A (2), SB-2 (2), SC 13D (2), 10-12G (1), 25-NSE (1), 8-A12B (1), CERTNAS (1), DEFR14A (1), FWP (1), NTN 10K (1), PRER14A (1), REGDEX/A (1), RW (1), S-1MEF (1), S-3ASR (1), SC 13D/A (1)
- Latest filingsAnnual report (10-K) Feb 24, 2026
Quarterly report (10-Q) Aug 11, 2026
Proxy statement (DEF 14A) Aug 26, 2026
Latest 8-K (8-K) Sep 14, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.0001 par value | CRDF | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 24, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks Cardiff Oncology, Inc. names in Item 1A of its 10-K filed Feb 24, 2026: 55 risks under these headings, as written.4
- Risks Related to Our Business
- We are a clinical stage company and may never earn a profit.
- We will need to raise substantial additional capital to develop and commercialize onvansertib and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.
- Management has performed an analysis and concluded that there exists a substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing on terms acceptable to us, if at all.
- Our product candidate, onvansertib, is in the early-mid stages of clinical development and its commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to successfully advance or develop our product candidate, our business will be materially harmed.
- Our product candidate may exhibit undesirable side effects when used alone or in combination with other approved pharmaceutical products or investigational new drugs, which may delay or preclude further development or regulatory approval, or limit their use if approved.
- If the results of preclinical studies or clinical trials for our product candidate, including those that are subject to existing or future license or collaboration agreements, are unfavorable or delayed, we could be delayed or precluded from the further development or commercialization of our product candidate, which could materially harm our business.
- If third party vendors upon whom we intend to rely on to conduct our preclinical studies or clinical trials do not perform or fail to comply with strict regulations, these studies or trials of our product candidate may be delayed, terminated, or fail, or we could incur significant additional expenses, which could materially harm our business.
- We have limited capacity for recruiting and managing clinical trials, which could impair our timing to initiate or complete clinical trials of our product candidate and materially harm our business.
- We, and our collaborators, must comply with extensive government regulations in order to advance our product candidate through the development process and ultimately obtain and maintain marketing approval for our products in the U.S. and abroad.
- We have limited experience in the development of therapeutic product candidates and therefore may encounter difficulties developing our product candidate or managing our operations in the future.
- Dependence on Third-Party Consultants
The other 45 risks
- Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
- Delays in clinical testing could result in increased costs to us and delay our ability to generate revenue.
- The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidate, our business will be substantially harmed.
- We may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval of our product candidate.
- If we fail to comply with healthcare regulations, we could face substantial enforcement actions, including civil and criminal penalties and our business, operations and financial condition could be adversely affected.
- If we are unable to satisfy regulatory requirements, we may not be able to commercialize our product candidate.
- Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
- If our product candidate is unable to compete effectively with marketed drugs targeting similar indications as our product candidate, our commercial opportunity will be reduced or eliminated.
- If the manufacturers upon whom we rely fail to produce our product candidate, in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of our product candidate.
- We may not be able to manufacture our product candidate in commercial quantities, which would prevent us from commercializing our product candidate.
- Materials necessary to manufacture our product candidate may not be available on commercially reasonable terms, or at all, which may delay the development and commercialization of our product candidate.
- Our product candidate, if approved for sale, may not gain acceptance among physicians, patients, and the medical community, thereby limiting our potential to generate revenues.
- Guidelines and recommendations published by various organizations can impact the use of our product.
- If third-party contract manufacturers upon whom we rely to formulate and manufacture our product candidate do not perform, fail to manufacture according to our specifications or fail to comply with strict regulations, our preclinical studies or clinical trials could be adversely affected and the development of our product candidate could be delayed or terminated or we could incur significant additional expenses.
- In the event that we need to change our third-party contract manufacturers, our preclinical studies, clinical trials or the commercialization of our product candidate could be delayed, adversely affected or terminated, or such a change may result in significantly higher costs.
- We do not currently have any internal drug discovery capabilities, and therefore we are dependent on in-licensing or acquiring development programs from third parties in order to obtain additional product candidates.
- If a product liability claim is successfully brought against us for uninsured liabilities, or such claim exceeds our insurance coverage, we could be forced to pay substantial damage awards that could materially harm our business.
- If we materially breach or default under the Nerviano Licensing Agreement, Nerviano will have the right to terminate the agreement and we could lose critical license rights, which would materially harm our business.
- We may delay or terminate the development of our product candidate at any time if we believe the perceived market or commercial opportunity does not justify further investment, which could materially harm our business.
- We will need to increase the size of our organization, and we may experience difficulties in managing growth.
- Business disruptions could seriously harm future revenue and financial condition and increase our costs and expenses.
- Security threats to our information technology infrastructure and/or our physical buildings could expose us to liability and damage our reputation and business.
- General economic or business conditions may have a negative impact on our business.
- If we use biological and hazardous materials in a manner that causes injury, we could be liable for damages.
- Healthcare reform measures could adversely affect our business.
- Catastrophic events, including global pandemics such as the COVID-19 pandemic, could materially adversely impact our business, results of operations and financial condition, including our clinical trials.
- Geopolitical risks associated with Russia’s invasion of Ukraine could result in increased market volatility and uncertainty, which could negatively impact our business, financial condition, and results of operations.
- The increasing use of social media platforms presents new risks and challenges.
- Volatile and significantly weakened global economic conditions have in the past and may in the future adversely affect our industry, business, and results of operations.
- Risks Related to Our Intellectual Property
- If we are unable to protect our intellectual property effectively, we may be unable to prevent third parties from using our technologies, which would impair our competitive advantage.
- The patents issued to us may not be broad enough to provide any meaningful protection, one or more of our competitors may develop more effective technologies, designs or methods without infringing our intellectual property rights and one or more of our competitors may design around our proprietary technologies.
- We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
- Certain rights that we in-license from third-parties are not within our control, and we may be negatively impacted if we lose those rights.
- Risks Related to Ownership of Our Common Stock
- Our ability to use our net operating loss carryforwards and certain other tax attributes is limited by Sections 382 and 383 of the Internal Revenue Code.
- Uncertainties in the interpretation and application of existing, new and proposed tax laws and regulations could materially affect our tax obligations and effective tax rate.
- The rights of the holders of our common stock may be impaired by the potential issuance of preferred stock.
- Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.
- We have not paid dividends on our common stock in the past and do not expect to pay dividends on our common stock for the foreseeable future. Any return on investment may be limited to the value of our common stock.
- If securities or industry analysts do not publish research or reports about our business, or if they adversely change their recommendations regarding our stock, our stock price and trading volume could decline.
- Delaware law and our corporate charter and bylaws contain anti-takeover provisions that could delay or discourage takeover attempts that stockholders may consider favorable.
- A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline and may impair our ability to raise capital in the future.
- We may be subject to stockholder litigation, thereby diverting our resources, which could materially adversely affect our profitability and results of operations.
- If we fail to comply with the continued minimum closing bid requirements of the Nasdaq or other requirements for continued listing, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.
- General Risk Factors
- If we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.
- We incur significant costs as a result of operating as a public company and our management expects to continue to devote substantial time to public company compliance programs.
Legal proceedings
The information called for by this item is incorporated herein by reference to the information set forth in "Note 9. Commitments and Contingencies” in the Notes to Consolidated Financial Statements included in Item 8 of this Report.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23SEC EDGARRoger Sidhu, Chief Medical Officer
- 24
- 25SEC EDGARTod Smeal, Chief Scientific Officer
- 26
- 27
- 28
- 29SEC EDGARMani Mohindru, Board member
- 30SEC EDGARRenee P. Tannenbaum, Board member
- 31SEC EDGARGary W. Pace, Board member
- 32SEC EDGARJames O. Armitage, Board member
- 33SEC EDGARLale White, Board member
- 34SEC EDGARMark Erlander, Board member
- 35SEC EDGARAthena Countouriotis, Board member
- 36SEC EDGARWilliam J. Welch, Board member
- 37SEC EDGARCarl B. Feldbaum, Board member
- 38SEC EDGARSteve Zaniboni, Board member
- 39SEC EDGARRodney S. Markin, Board member
- 40SEC EDGARChristopher McGuigan, Board member
- 41SEC EDGARJohn P. Brancaccio, Board member
- 42SEC EDGARStanley Tennant, Board member
- 43SEC EDGARGabriel Cerrone, Board member
- 44SEC EDGARGary S. Jacob, Board member
- 45SEC EDGARAbba David Poliakoff, Board member
- 46SEC EDGARKira Sheinerman, Board member
- 47
- 48SEC EDGARResults of operations
- 49
- 50SEC EDGARShareholder vote
- 51SEC EDGARRegulation FD disclosure
- 52SEC EDGAREntered a material agreement
- 53SEC EDGAROther events
- 54SEC EDGARResults of operations
- 55
- 56
- 57SEC EDGARRegulation FD disclosure
- 58SEC EDGARCompleted an acquisition or sale
- 59NasdaqNasdaq calendar
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75